Abstract: The present invention relates to compositions comprising an interleukin-12 (IL-12) protein having a first and second subunit, an extra domain B (ED-B)-binding domain, and a linker between the IL-12 protein and the ED-B-binding domain.

Abstract: This invention relates to stable formulations that can be prepared to high concentration of active agent using low amounts of detergents and to methods for producing such formulations. In particular, this invention relates to formulations containing the L19-TNF? immunocytokine.

Abstract: The present invention relates to immunoconjugates, compositions, methods and uses for treating brain tumors, especially glioma, by administration of a tumour necrosis factor alpha (TNF?) immunoconjugate.

Abstract: The application relates to the diagnosis and treatment of diseases, including cancer, autoimmune diseases and inflammatory disorders. The invention provides, and involves the use of, antibody molecules that bind fibroblast activation protein (FAP) from humans, sheep, pigs and domestic dogs. The antibody molecules may be conjugated to a pro-inflammatory agent, an anti-inflammatory agent, a biocidal molecule, a cytotoxic molecule, or a radioisotope.

Abstract: The present invention relates to a dosage unit or regimen, recombinant protein for use, method or formulation of a recombinant protein comprising interleukin-12 (IL-12) and an antibody binding the extra-domain B (ED-B) of fibronectin, or a target binding fragment or derivative thereof.

Abstract: The present application relates to the treatment of pulmonary hypertension (PH) using interleukin-9 (IL9) and particularly, although not exclusively, to the treatment of PH using IL9 conjugated to a specific binding member that binds an antigen associated with tissue and/or vascular remodelling, such as the Extra Domain-A (ED-A) of fibronectin. Conjugates comprising a specific binding member that binds an antigen associated with tissue and/or vascular remodelling, such as ED-A, and IL9 that are suitable for the treatment of PH, in particular conjugates in which IL9 is conjugated to a single-chain Fv that binds ED-A or in which IL9 is conjugated an IgG that binds ED-A, are also disclosed.

Abstract: The present invention relates to immunoconjugates, compositions, methods and uses for treating brain tumors, especially glioma, by administration of a tumour necrosis factor alpha (TNF?) immunoconjugate.

Abstract: This invention relates to stable formulations that can be prepared to high concentration of active agent using low amounts of detergents and to methods for producing such formulations. In particular, this invention relates to formulations containing the L19-TNF? immunocytokine.

Abstract: This invention relates to stable formulations that can be prepared to high concentration of active agent using low amounts of detergents and to methods for producing such formulations. In particular, this invention relates to formulations containing the L19-TNF? immunocytokine.

Abstract: The present application relates to conjugates comprising interleukin 2 (IL2), and a tumour necrosis factor, such as tumour necrosis factor alpha (TNF?), and an antibody molecule. The antibody molecule preferably binds to an antigen associated with neoplastic growth and/or angiogenesis, such as the Extra-Domain A (EDA) of fibronectin. The conjugate may be used in the treatment of cancer.

Abstract: The present application relates to conjugates comprising interleukin 2 (IL2), and a mutant of tumour necrosis factor, such as tumour necrosis factor alpha (TNF?), and an antibody molecule. The antibody molecule preferably binds to an antigen associated with neoplastic growth and/or angiogenesis, such as the Extra-Domain A (EDA) or Extra-Domain B (EDB) of fibronectin. The conjugate may be used in the treatment of cancer.

Abstract: The present invention relates to variants of the anti-tenascin antibody F16 which are modified to abolish N-glycosylation at positions 88 to 90 in the VL domain. This results in dramatically improved properties, such as improved binding affinity and tumour biodistribution in vivo. Variant F16 antibody molecules and methods for their production and use are provided.

Abstract: The application relates to a conjugate comprising interleukin-22 (IL22) and an antibody molecule. The antibody molecule preferably binds an antigen associated with angiogenesis, such as the ED-A isoform of fibronectin. In particular, the application relates to the therapeutic use of such conjugates in the treatment of a disease/disorder, such as autoimmune diseases, including inflammatory bowel disease (IBD).

Abstract: The invention relates to the diagnosis and treatment of diseases, including inflammatory disorders, proliferative disorders and autoimmune diseases. The invention provides, and involves the use of, antibody molecules that bind: i) lysozyme, ii) neutrophil elastase, iii) tissue inhibitor of metalloproteinase-1 (TIMP-1), or iv) the D domain of Tenascin-C. The invention also relates to the use of antibody molecules that bind v) the IIICS isoform of fibronectin, vi) the Extra Domain-B (ED-B) of fibronectin, vii) matrix-metalloproteinase 3 (MMP3), or viii) the A1 domain of tenascin-C in the diagnosis and treatment of inflammatory disorders such as inflammatory bowel disease.

Abstract: The invention relates to a binding member that binds the Extra Domain-A (ED-A) isoform of fibronectin for the detection and treatment of rheumatoid arthritis.

Abstract: The invention relates to an antibody-drug conjugate and an immunocytokine for use in the treatment of a neoplastic or inflammatory disease, as well as molecules comprising an antibody-drug conjugate and an immunocytokine.

Abstract: The application relates to a conjugate comprising interleukin-22 (IL22) and an antibody molecule. The antibody molecule preferably binds an antigen associated with angiogenesis, such as the ED-A isoform of fibronectin. In particular, the application relates to the therapeutic use of such conjugates in the treatment of a disease/disorder, such as autoimmune diseases, including inflammatory bowel disease (IBD).

Abstract: The present application relates to conjugates comprising interleukin 2 (IL2), and a tumour necrosis factor, such as tumour necrosis factor alpha (TNF?), and an antibody molecule. The antibody molecule preferably binds to an antigen associated with neoplastic growth and/or angiogenesis, such as the Extra-Domain A (EDA) of fibronectin. The conjugate may be used in the treatment of cancer.

Abstract: The application relates to a conjugate comprising interleukin-22 (IL22) and an antibody molecule. The antibody molecule preferably binds an antigen associated with angiogenesis, such as the ED-A isoform of fibronectin. In particular, the application relates to the therapeutic use of such conjugates in the treatment of a disease/disorder, such as autoimmune diseases, including inflammatory bowel disease (IBD).

Abstract: Specific binding members that bind the ED-A isoform of fibronectin for use in methods of treatment, diagnosis, detection and/or imaging of inflammatory bowel disease (IBD), and/or for use in delivery to the IBD tissue of a molecule conjugated to the specific binding member. The specific binding member may, for example, be conjugated to an immunosupressive or anti-inflammatory molecule, such as interleukin-10.